Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm says drug could have some potential in treatment of fibromyalgia syndrome.

You may also be interested in...



Taking A Deep Breath: Novartis & Schering Split Respiratory Product Rights, Giving Novartis Indacaterol

Novartis is building a respiratory franchise based around its promising chronic obstructive pulmonary disease drug QAB149 (indacaterol) and is taking steps to make sure the world knows it

Taking A Deep Breath: Novartis & Schering Split Respiratory Product Rights, Giving Novartis Indacaterol

Novartis is building a respiratory franchise based around its promising chronic obstructive pulmonary disease drug QAB149 (indacaterol) and is taking steps to make sure the world knows it

Novartis And Schering-Plough Back Off Their Respiratory Collaboration

Schering and Novartis divide up the fruits of their labor to date, as Novartis touts its growing respiratory franchise and Schering gets ready for acquisition by Merck.

Related Content

Topics

UsernamePublicRestriction

Register

PS066618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel